Abstract 63 Table 1

	Disease Free Survival (DFS)					
	Univariate			Multivariable		
	HR	95%CI	p-value	HR	95%CI	p-value
Age	1,046	(1,007 – 1,086)	0.021	1,036	(0,992 – 1,082)	0,114
BMI	1,046	(0,994 – 1,101)	0.085			
CCI >3	1,880	(1,011 – 3,494)	0.046	1,683	(0,840 – 3,373)	0,142
ASA >2	2,356	(1,237 – 4,484)	0.009	1,880	(0,906 – 3,900)	0.39
Laparoscopic approach	1,255	(0,705 – 2,237)	0,440			
LND performed	1,698	(0,925 – 3,117)	0,87			
Extra-uterine disease	3,430	(1,965 – 6,006)	<0,001	3,468	(1,530 – 7,828)	0,003
Positive node(s)	3,552	(1,977 – 6,381)	<0,001	1,458	(0,630 – 3,376)	0,379
	Overall Survival (OS)					
	Univariate			Multivariable		
	HR	95%CI	p-value	HR	95%CI	p-value
Age	1,098	(1,048 – 1,151)	<0,001	1,096	(1,044 -1,150)	<0,001
BMI	1,047	(0,989 – 1,109)	0,110			
CCI >3	2,010	(0,978 – 4,113)	0,058			
ASA >2	3,001	(1,470 – 6,127)	0,003	1,715	(0,822 – 3,582)	0,151
Laparoscopic approach	1,469	(0,754 – 2,859)	0,223			
LND performed	2,589	(1,411 – 4,750)	0,002	1,701	(0,889 – 3,254)	0,578
Extra-uterine disease	2,281	(1,268 – 4,102)	0,006	2,571	(1,406 – 4,701)	0,002
Positive node(s)	2,263	(1,196 – 4,280)	0,018	2,316	(0,527 -10,167)	0,266

Legend: HR=Hazard Ratio. CI=Confidence Interval. BMI=Body Mass Index [weight (kg)/height (m²)]. CCI=Charlson Comorbidity Index. ASA=American Society of Anaesthesiologists.

IGCS19-0274

64

PREDICTORS OF POSTOPERATIVE MORBIDITY AFTER CYTOREDUCTIVE SURGERY FOR ADVANCED OVARIAN CANCER: ANALYSIS AND MANAGEMENT OF COMPLICATIONS

V Di Donato*, A Di Pinto, E Benedetti, I Palaia, G Perniola, M Schiavi, A Musella, F Tomao, L Muzii, P Benedetti Panici. *University Sapienza, Department of gynecological obstetrical and urological sciences., Rome, Italy*

10.1136/ijgc-2019-IGCS.64

Objectives To evaluate a correlation between pre-surgical condition as predictor of overall, severe complications and 90 days mortality in patients undergoing cytoreductive surgery for advanced ovarian cancer.

Methods Consecutive patients affected by advanced ovarian cancer who have undergone cytoreduction surgery were

considered for the study. Patients' characteristics' and surgical data were recorded. Modified Frailty Index (mFI) was evaluated. Higher mFI scores indicated more severe comorbidities. Postoperative complications were evaluated and graded according to Accordion score. Logistic regression was used to evaluate the associations between clinical and surgical variables and severe or overall complications.

Results 263 patients were included. 86 patients developed at least one complication: 70 (26.6%) of these reported mild complications, 13 (4.9%) developed severe complications, 3 (1.1%) died within 90 days from surgery. At multivariate analysis logistic regression mFI>3 (OR: 1.67, CI 95% 1.08–2.81; p=0.05) the complexity of surgical procedures performed (OR: 4.15, CI 95% 2.38–7.23; p<0.001) were independent predictors of overall complications, while BMI>30 (OR: 5.13, CI 95%:1.15–22.92, p=0.03), mFI>3 (OR:2.45,CI95%:1.06–5.67;p=0.04),high complexity surgery executed (OR:12.31, CI95%:3.08–47.74;p<0.001) were independent predictors of severe complications.

Conclusions mFI and high complexity surgery are predictive of Severe and Overall Complications. Patients' pre-operative care profile evaluation may guide specialists in reducing, preventing and managing complications correctly. mFI seems to be effective in identify high-risk patients and represent a valuable tool to help health professionals in providing risk counseling and discussion of management for women undergoing surgery for gynecologic cancer.

Breast Plenary

IGCS19-0175

65

MRI-BASED PREDICTIVE FACTORS OF AXILLARY LYMPH NODE METASTASES IN BREAST CANCER

¹D Atallah, ²M Moubarak*, ¹W Arab, ¹N El Kassir, ³G Chahine, ⁴M Ghossain, ⁴C Salem. ¹saint Joseph University, Obstetrics and Gynecology, Beirut, Lebanon; ²Saint Joseph University, Obstetrics and Gynecology, Beirut, Lebanon; ³Saint Joseph University, Oncology, Beirut, Lebanon; ⁴Saint Joseph University, Radiology, Beirut, Lebanon

10.1136/ijgc-2019-IGCS.65

Objectives To determine the accuracy of MRI in detecting axillary lymph nodes (ALNs) metastases preoperatively and to define predictive characteristics of ALN involvement in patients with invasive breast cancer.

Methods Breast MR (3 Tesla) examinations of 169 patients with invasive breast cancer were reviewed at Hôtel-Dieu de France Hospital. Morphological parameters in addition to apparent diffusion coefficient (ADC) value were compared with pathological nodal status.

Results The sensitivity and specificity of MRI in detecting ALN involvement were 87.5% and 55.6% respectively. The negative and positive predictive value of MRI was 81.64% and 66.34% respectively. The mean size of metastatic ALN was larger than that of negative ALN (13.9 mm vs. 10.9 mm, $p = 0.000$). ALNs larger than 12 mm were associated with higher risk of metastases ($p = 0.000$). The asymmetry of size between ipsilateral and contralateral ALNs was more significant in positive ALNs on pathology ($p = 0.008$ vs. 0.043). In a univariate analysis, the round shape of ALN, loss of fatty hilum, irregular contours and hypo-intensity/heterogeneous intensity on T2-weighted sequence were significantly predictive of lymph node metastasis ($p = 0.000$ for the four characteristics). In a multivariate analysis, only the round shape of lymph node and the hypo-intensity/heterogeneous intensity on T2-weighted sequence were significantly associated with lymph node metastasis ($p = 0.01$ and $p = 0.018$ respectively). The ADC value of ALN did not aid the differentiation between benign and metastatic lymph nodes ($p = 0.862$).

Conclusions Conventional MRI using the ALN shape and the signal intensity in T2-weighted sequences can evaluate the axilla with high sensitivity.

IGCS19-0128

66

SHOULD WE OFFER MULTI-GENE TESTING TO ALL PATIENTS WITH BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS

^{1,2}L Sun, ³A Brentnall, ²S Patel, ⁴D Buist SM, ⁴E Bowles JA, ⁵DG Evans R, ⁶D Eccles, ⁷J Hopper, ⁷S Li, ³S Duffy, ³J Cuzick, ⁸I dos-Santos-Silva, ¹Z Sadique, ⁹L Yang, ¹R Legood, ^{2,10,11}R Manchanda*. ¹London School of Hygiene and Tropical Medicine, Department of Health Services Research and Policy, London, UK; ²Barts Cancer Institute- Queen Mary University of London, Centre for Experimental Cancer Medicine, London, UK; ³Wolfson Institute of Preventive Medicine- Queen Mary University of London, Centre for Cancer Prevention, London, UK; ⁴Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington Health Research Institute, Seattle, USA; ⁵The University of Manchester, Genomic Medicine- Manchester Academic Health Science Centre MAHSC- Manchester Universities Foundation Trust- St. Mary's Hospital, London, UK; ⁶University of Southampton, Cancer Sciences Academic Unit- Faculty of Medicine and Cancer Sciences, Southampton, UK; ⁷University of Melbourne, Centre for Epidemiology and Biostatistics- Melbourne School of Population and Global Health- Faculty of Medicine- Dentistry and Health Sciences, Melbourne, Australia; ⁸London School of Hygiene and Tropical Medicine, Department of Non-communicable Disease Epidemiology, London, UK; ⁹Peking University, School of Public Health, Beijing, China; ¹⁰Barts Health NHS Trust- Royal London Hospital, Department of Gynaecological Oncology, London, UK; ¹¹University College London, MRC Clinical Trials Unit at UCL- Institute of Clinical Trials and Methodology- Faculty of Population Health Sciences, London, UK

10.1136/ijgc-2019-IGCS.66

Objectives To estimate incremental lifetime-effects, costs, cost-effectiveness and population impact of multigene-testing all BC patients compared to current practice of family-history/clinical-criteria based genetic (BRCA)-testing.

Methods Cost-effectiveness microsimulation modelling study comparing lifetime costs-&-effects of BRCA1/BRCA2/PALB2 (multigene) testing all unselected BC-cases (Strategy-A) with family-history/clinical-criteria based BRCA1/BRCA2-testing (Strategy-B) in both UK and US populations. Data obtained from 11,836 population-based BC-patients (regardless of family-history) recruited to four large research studies in the UK (Predicting-Risk-of-Breast-Cancer-at-Screening (PROCAS: 1389 out of 57,000 women) & Prospective-Outcomes-in-Sporadic-versus-Hereditary-breast-cancer (POSH: 2885) studies); US (Kaiser-Permanente Washington Breast-Cancer-Surveillance-Consortium (BCSC) registry: 5892 out of 132,139 women) and Australia (Population-based BC-cases of the Australian-Breast-Cancer-Family-Study (ABCFS: 1670 women)). The main outcome measure was the incremental cost per quality-adjusted life-year (QALY) gained with a 3.5% annual discount. Parameter uncertainty was explored using one-way and probabilistic sensitivity analyses.

Results Compared with current clinical-criteria/family-history-based BRCA-testing, (BRCA1/BRCA2/PALB2) multigene-testing for all BC-patients would cost £10,470/QALY (UK) or \$58,702/QALY (US) gained, well below UK/NICE and US cost-effectiveness thresholds of £30,000/QALY & \$100,000/QALY. Probabilistic sensitivity-analysis shows unselected multigene-testing remains cost-effective for 98% UK/77% US health-system simulations. One year's unselected panel-genetic testing can prevent 1,776 BC/OC-cases and 557 deaths in the